Aptinyx to Participate in William Blair Biotech Focus Conference 2021
Aptinyx (Nasdaq: APTX), a biopharmaceutical company, announced that its CEO, Norbert Riedel, Ph.D., will participate in the Updates in Neuropsych panel at the William Blair Biotech Focus Conference on July 15 at 12:00 p.m. ET.
A live webcast of the event will be available on the company's website and archived for 30 days. Aptinyx is focused on developing therapies for nervous system disorders, including chronic pain and PTSD, through a unique mechanism that modulates NMDA receptors, enhancing synaptic plasticity. For more information, visit www.aptinyx.com.
- None.
- None.
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m. ET.
A live webcast of the presentation will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Source: Aptinyx Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005185/en/
FAQ
What announcement did Aptinyx Inc. make on July 15 regarding a conference?
Where can I watch the Aptinyx conference presentation?
What is the focus of Aptinyx's drug development?
What is the unique mechanism used by Aptinyx's therapies?
How long will the web archive of the Aptinyx presentation be available?
